Article
[Pharmacogenetic features of the effect of metformin in patients with coronary heart disease in the presence of metabolic syndrome and type 2 diabetes mellitus in terms of PPAR-gamma2 gene polymorphism].
Terapevticheskii arkhiv - 1 Jan 2012
Lavrenko A V, Shlykova O A, Kutsenko L A, Mamontova T V, Kaĭdashev I P
Abstract excerpt
AIM: To define the pharmacogenetic features of the effect of metformin in coronary heart disease (CHD) patients with metabolic syndrome (MS) or type 2 diabetes mellitus (T2DM), by taking into consideration PPAR-gamma2 Pro1 2Ala polymorphism. SUBJECTS AND METHODS: Twenty-four men with CHD and MS and 28 men with CHD and T2DM were examined. The effect of metformin as a short course in combination therapy was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.